

## Drug Monograph

Drug/Drug **Injectafer (ferric carboxymaltose) Injection / Iron Salt**

Class:

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
<b>Dosage Forms:</b>	Each Injectafer 15mL single-use vial is a solution containing 750mg ferric carboxymaltose for intravenous use.	
<b>Manufacturer:</b>	American Regent, Inc. Shirley, NY 11967	
<b>Indications:</b>	Injectafer is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron and those who have non-dialysis dependent chronic kidney disease.	
<b>Costs:</b>	\$ 750.00 per 15 mL vial of Injectafer. Wholesale Acquisition Cost	
<b>Summary of Findings:</b>	MO HealthNet Division recommends continued Prior Authorization status for this product.	
<b>Status Recommendation:</b>	<input checked="" type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PDL
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Preferred Agent
	<input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> PA Required

Prepared By: Kara Lincoln, Pharm. D Candidate

Date: September 18, 2013